Stability-Indicating RP-HPLC Method Development and Validation for Ibuprofen Across Three Advanced Drug Delivery Systems: Liposomes, PLGA Nanoparticles and a Transdermal Patch

References

[1] Soppimath KS, Aminabhavi TM, Kulkarni AR, Rangarajan A. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1–2):1–20.

[2] Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55(1):R1–R4.

[3] Peraman R, Bhadraya K, Padmanabha Reddy Y. Analytical quality by design: a tool for regulatory flexibility and robust analytics. Int J Anal Chem. 2015;2015:868727.

[4] Klick S, Muijselaar PG, Waterval J, Eichinger T, Korn C, Gerding TK, et al. Towards a generic approach for stress testing of drug substances and drug products. Pharm Technol. 2005;29(2):48–66.

[5] Singh C, Rao K, Yadav N, Bansal N, Vashist Y, Kumari S, Chugh P. A review: drug–excipient incompatibility by FTIR spectroscopy. Curr Pharm Anal. 2023;19(5):371–378.

[6] Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102.

[7] Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1–2):271–284.

[8] Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123–133.

[9] Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145–160.

[10] Bakshi M, Singh S. Development of validated stability-indicating assay methods — critical review. J Pharm Biomed Anal. 2002;28(6):1011–1040.

[11] Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs — a review. J Pharm Anal. 2014;4(3):159–165.

[12] Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000;21(23):2475–2490.

[13] Alsante KM, Ando A, Brown R, Ensing J, Hatajik TD, Kong W, Tsuda Y. The role of degradant profiling in active pharmaceutical ingredients and drug products. Adv Drug Deliv Rev. 2007;59(1):29–37.

[14] Reynolds DW, Facchine KL, Mullaney JF, Alsante KM, Hatajik TD, Motto MG. Available guidance and best practices for conducting forced degradation studies. Pharm Technol. 2002;26(2):48–56.

[15] Singh S, Bakshi M. Guidance on the conduct of stress tests to determine inherent stability of drugs. Pharm Technol. 2000;24(4):1–14.

[16] Grimm W. Extension of the International Conference on Harmonization Tripartite Guideline for stability testing to climatic zones III and IV. Drug Dev Ind Pharm. 1998;24(4):313–325.

[17] Waterman KC, Adami RC. Accelerated aging: prediction of chemical stability of pharmaceuticals. Int J Pharm. 2005;293(1–2):101–125.

[18] Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10(2):57.

[19] Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.

[20] Alexander A, Dwivedi S, Ajazuddin, Giri TK, Saraf S, Saraf S, Tripathi DK. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J Control Release. 2012;164(1):26–40.

[21] Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505–522.

[22] Clas SD, Dalton CR, Hancock BC. Differential scanning calorimetry: applications in drug development. Pharm Sci Technol Today. 1999;2(8):311–320.

[23] Giron D. Thermal analysis and calorimetric methods in the characterisation of polymorphs and solvates. Thermochim Acta. 1995;248:1–59.

[24] Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.

[25] Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. 2015;10:975–999.

[26] Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018;26(1):64–70.

[27] Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71.

[28] Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, et al. Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. J Pharm Sci. 2005;94(10):2121–2131.

[29] Holčapek M, Jirásko R, Lísa M. Recent developments in liquid chromatography–mass spectrometry and related techniques. J Chromatogr A. 2012;1259:3–15.

[30] Singh S, Junwal M, Modhe G, Tiwari H, Kurmi M, Parashar N, Sidduri P. Forced degradation studies to assess the stability of drugs and drug products. TrAC Trends Anal Chem. 2013;49:71–88.

[31] Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2–3):165–196.

[32] Bhattacharjee S. DLS and zeta potential — what they are and what they are not. J Control Release. 2016;235:337–351.

[33] Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991–1003.

[34] International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products. ICH; 2003.

[35] International Council for Harmonisation. ICH Q1B: Photostability Testing of New Drug Substances and Products. ICH; 1996.

[36] International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. ICH; 2022.

[37] International Council for Harmonisation. ICH Q3B(R2): Impurities in New Drug Products. ICH; 2006.

[38] International Council for Harmonisation. ICH Q8(R2): Pharmaceutical Development. ICH; 2009.

[39] US Food and Drug Administration. Analytical Procedures and Methods Validation for Drugs and Biologics: Guidance for Industry. Silver Spring (MD): CDER; 2015.

[40] World Health Organization. Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products. WHO Technical Report Series No. 953, Annex 2. Geneva: WHO; 2009.

[41] European Medicines Agency. Guideline on Stability Testing for Applications for Variations to a Marketing Authorisation. CPMP/QWP/576/96 Rev 1. London: EMA.

@article{1724045,
      author = {Akhileshwar Ram Mishra, Dr. Arpita Mishra},
      title = {Stability-Indicating RP-HPLC Method Development and Validation for Ibuprofen Across Three Advanced Drug Delivery Systems: Liposomes, PLGA Nanoparticles and a Transdermal Patch},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {4},
      pages = {2456-2465},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1724045.pdf},
      abstract = {Advanced drug delivery systems (ADDS) — liposomes, polymeric nanoparticles and transdermal patches — markedly improve the pharmacokinetic and targeting profile of poorly soluble drugs, yet the absence of validated, stability-indicating analytical methods (SIAMs) for these complex matrices remains a significant barrier to their regulatory approval and routine quality control [1,6,9]. This study developed and validated a reversed-phase high-performance liquid chromatography (RP-HPLC) SIAM for ibuprofen — a Biopharmaceutics Classification System (BCS) Class II model drug — formulated as three distinct ADDS platforms: liposomes prepared by thin-film hydration and membrane extrusion, poly(lactic-co-glycolic acid) (PLGA) nanoparticles prepared by nanoprecipitation, and a matrix-type transdermal patch prepared by solvent casting. All three formulations were physicochemically characterised and subjected to forced degradation under acidic, alkaline, oxidative, photolytic and thermal stress per ICH Q1A(R2)/Q1B guidance. The developed RP-HPLC method resolved ibuprofen from five structurally distinct degradation products and was fully validated per ICH Q2(R2) (linearity r² = 0.99999 over 5–200 μg/mL; accuracy 99.4–100.1%; precision %RSD ≤ 0.78%; LOD 0.24 μg/mL; LOQ 0.71 μg/mL). Six-month long-term and accelerated stability studies demonstrated that all three ADDS retained ≥ 92% assay, with first-order degradation kinetics predicting shelf lives of 27–39 months. Strong inverse correlations (r = −0.92 to −0.96) linked chemical degradation to physical critical-quality-attribute (CQA) drift, together providing an integrated chemo-physical quality-assurance template applicable to ADDS development more broadly.},
      keywords = {advanced drug delivery systems; stability-indicating analytical method; RP-HPLC; ibuprofen; forced degradation; ICH Q2(R2); liposomes; PLGA nanoparticles; transdermal patch; shelf-life prediction},
      month = {October},
  }